Author(s)

David C. Pryde, Thien-Duc Tran, Mark Gardner, Chris Pickford, Stephen M. Shaw, Mike Westby, Tanya Parkinson, Caroline Smith-Burchnell, Rob Webster, Satish Dayal

Anti-Infectives Research Unit, Pfizer Global Research and Develoapment, Sandwich, UK.
Anti-Infectives Research Unit, Pfizer Global Research and Development, Sandwich, UK.
Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Sandwich, UK.
Worldwide Medicinal Chemistry, Pfizer Global Research and Development, Sandwich, UK.

A high throughput screen of the Pfizer compound collection was carried out using a hepatitis C virus (HCV) genotype 1b subgenomic replicon cell line. Those confirmed hits that demonstrated broad spectrum activity without overt cytotoxicity were further evaluated, leading to the identification of a series of pyrrolopyridines with excellent antiviral activity in a fully infectious HCV cell-based assay and pharmacokinetic properties.

HCV; Replicon; Antiviral; Cell-Based Screen

D. Pryde, T. Tran, M. Gardner, C. Pickford, S. Shaw, M. Westby, T. Parkinson, C. Smith-Burchnell, R. Webster and S. Dayal, "Identification of HCV Inhibitors from a Cell-Based Sub-Genomic Replicon Screen," Open Journal of Medicinal Chemistry, Vol. 3 No. 1, 2013, pp. 16-25. doi: 10.4236/ojmc.2013.31003.